| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jun 5, 2020 | TXMD Therapeuticsmd, Inc. | Finizio Robert G | CEO | Buy | 30,000 | $1.15 | $34,600.00 | - | |
| Jun 5, 2020 | BHC Bausch Health Companies Inc. | Valueact Holdings, L.P.73 | Director, See Remarks | Buy | 948,353 | $19.24 | $18,246,311.72 | +5.6% | |
| Jun 5, 2020 | PCRX Pacira Biosciences, Inc. | Riker Lauren Bullaro76 | Vice President, Finance | Sell | 2,631 | $47.69 | $125,469.19 | -13.1% | |
| Jun 5, 2020 | PCRX Pacira Biosciences, Inc. | Williams Kristen Marie76 | Chief Administrative Officer | Sell | 8,306 | $47.95 | $398,280.50 | -23.1% | |
| Jun 4, 2020 | AQST Aquestive Therapeutics, Inc. | Kendall Keith J | CEO And President | Sell | 50,000 | $5.11 | $255,310.00 | -7.3% | |
| Jun 4, 2020 | PCRX Pacira Biosciences, Inc. | Laranjeira Charles Anthony61 | SVP, Technical Operations | Sell | 863 | $46.33 | $39,983.65 | -7.9% | |
| Jun 4, 2020 | TXMD Therapeuticsmd, Inc. | Bisaro Paul | Director | Buy | 50,000 | $1.14 | $57,000.00 | New | |
| Jun 4, 2020 | TXMD Therapeuticsmd, Inc. | Thompson Tommy G51 | Director | Buy | 8,700 | $1.13 | $9,831.00 | +1.3% | |
| Jun 4, 2020 | PCRX Pacira Biosciences, Inc. | Reinhart Charles A. III64 | Chief Financial Officer | Sell | 1,489 | $46.33 | $68,986.86 | -9.1% | |
| Jun 4, 2020 | PCRX Pacira Biosciences, Inc. | Hastings Paul J75 | Director | Sell | 2,025 | $47.46 | $96,106.50 | -29.4% | |
| Jun 4, 2020 | PCRX Pacira Biosciences, Inc. | McLoughlin Dennis64 | Chief Commercial Officer | Sell | 1,447 | $46.33 | $67,040.96 | -8.9% | |
| Jun 4, 2020 | AMPH Amphastar Pharmaceuticals, Inc. | Zhou Rong59 | EVP, Production Center | Sell | 22,969 | $18.98 | $435,854.78 | -12.6% | |
| Jun 4, 2020 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 14,965 | $9.68 | $144,850.56 | -0.1% | |
| Jun 4, 2020 | HROW Harrow, Inc. | Opaleye Management Inc.60 | 10% Owner | Buy | 50,000 | $5.73 | $286,508.30 | +0.7% | |
| Jun 4, 2020 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 28,000 | $0.38 | $10,679.60 | - | |
| Jun 3, 2020 | EBS Emergent Biosolutions Inc. | Richard Ronald | Director | Sell | 6,572 | $87.51 | $575,142.01 | -60.6% | |
| Jun 3, 2020 | EBS Emergent Biosolutions Inc. | Bailey Sue | Director | Sell | 5,322 | $87.50 | $465,690.97 | -12.5% | |
| Jun 3, 2020 | TAK Takeda Pharmaceutical Co Ltd | Shire Human Genetic Therapies, Inc. | 10% Owner | Sell | 40,086 | $19.75 | $791,698.50 | -0.6% | |
| Jun 2, 2020 | TAK Takeda Pharmaceutical Co Ltd | Shire Human Genetic Therapies, Inc. | 10% Owner | Sell | 213,867 | $19.81 | $4,237,024.07 | -0.8% | |
| Jun 2, 2020 | COLL Collegium Pharmaceutical, Inc | Ciaffoni Joseph | President And CEO | Sell | 76,537 | $21.45 | $1,641,766.95 | -8.9% | |
| Jun 1, 2020 | AKBA Akebia Therapeutics, Inc. | Faulkingham Dell70 | CCO | Sell | 6,426 | $11.58 | $74,413.08 | -8.0% | |
| Jun 1, 2020 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $18.97 | $9,483.40 | -0.7% | |
| Jun 1, 2020 | ZTS Zoetis Inc. | Chen Heidi C.47 | Executive Vice President | Sell | 1,179 | $138.65 | $163,468.35 | -6.7% | |
| May 29, 2020 | SNY Sanofi | Sanofi | 10% Owner | Sell | 22,821,451 | $0.00 | - | -98.3% | |
| May 29, 2020 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 60,633 | $0.38 | $22,890.53 | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.